中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

脂肪量和肥胖相关基因多态性与非酒精性脂肪性肝病易感性的关系

马磊 郝岸华 胡欣欣 赵真真 周林 辛永宁

引用本文:
Citation:

脂肪量和肥胖相关基因多态性与非酒精性脂肪性肝病易感性的关系

DOI: 10.3969/j.issn.1001-5256.2022.12.009
基金项目: 

国家自然科学基金 32171277

伦理学声明:本研究遵守国家所有相关法规、机构政策和赫尔辛基宣言,并于2017年10月11日经由青岛市市立医院伦理委员会审批,批号:2017临审字第20号(快)。所纳入患者均签署知情同意书。
利益冲突声明:本研究不存在研究者、伦理委员会成员、受试者监护人以及与公开研究成果有关的利益冲突。
作者贡献声明:马磊、辛永宁负责课题设计,资料分析,撰写论文;郝岸华、胡欣欣、赵真真、周林参与收集数据,修改论文;马磊负责拟定写作思路,指导撰写文章并最后定稿。
详细信息
    通信作者:

    辛永宁,xinyongning@163.com

Association of fat mass- and obesity-associated gene (FTO) polymorphisms with susceptibility to nonalcoholic fatty liver disease

Research funding: 

National Natural Science Foundation of China 32171277

More Information
  • 摘要:   目的  探讨我国青岛地区汉族人群脂肪量和肥胖相关基因(FTO) rs1421085、rs9939609、rs8050136多态性与非酒精性脂肪性肝病(NAFLD)易感性的关系。  方法  纳入自2018年6月—2019年6月就诊于青岛市市立医院及城阳区人民医院的NAFLD患者(119例)及体检人群(187例)。采集参与者基本信息,抽取空腹静脉血并检测生化指标。提取全血DNA并采用聚合酶链式反应结合测序的方法鉴定FTO基因多态性。计量资料两组间比较采用t检验或Mann-Whitney U检验,基因型分布等定性资料两组间比较采用χ2检验,并计算等位基因频率风险系数比值比和95%CI,评估等位基因与NAFLD风险的关系。  结果  NAFLD和对照组基本信息进行比较,两组间年龄、BMI、ALT、GGT、TG及胆红素(Bil)差异均具有统计学意义(P值均<0.05)。基因型鉴定结果显示,rs1421085(TT、CT、CC),rs8050136(TT、CT、CC),rs9939609(TT、AT、AA)位点均具有3种基因型。NAFLD和对照组中FTO rs1421085、rs9939609、rs8050136等位基因频率和基因型比较,分布差异均无统计学意义(P值均>0.05)。对不同基因型携带者进行比较,各临床指标差异亦均无统计学意义(P值均>0.05)。  结论  青岛地区汉族人群FTO rs1421085、rs9939609、rs8050136多态性与NAFLD易感性无显著关系。

     

  • 表  1  FTO基因引物序列

    Table  1.   Primer sequence of FTO gene

    位点 引物名称 引物序列5′-3′
    rs9939609 primer 1 ACGTTGGATGTTCTAGGTTCCTTGCGACTG
    primer 2 ACGTTGGATGTCCCACTCCATTTCTGACTG
    rs1421085 primer 1 ACGTTGGATGGTAGCAGTTCAGGTCCTAAG
    primer 2 ACGTTGGATGGGAGACTACCCTACAAATTC
    rs8050136 primer 1 ACGTTGGATGTGACAGTGCCAGCTTCATAG
    primer 2 ACGTTGGATGAAGGCAAAAACCACAGGCTC
    下载: 导出CSV

    表  2  两组一般临床资料及相关实验室指标比较

    Table  2.   Comparison of general clinical data and related laboratory indicators between NAFLD and control group

    项目 NAFLD(n=119) 对照组(n=187) 统计值 P
    年龄(岁) 43.00(39.00~45.25) 48.00(42.50~59.00) Z=-5.489 <0.001
    男/女(例) 34/25 78/46 χ2=0.469 0.494
    BMI(kg/m2) 26.44±2.57 23.88±3.24 t=5.891 <0.001
    ALT(U/L) 23.71(18.94~44.49) 18.87(13.56~25.71) Z=-4.977 <0.001
    AST(U/L) 23.65±8.00 22.35±8.46 t=1.111 0.268
    GGT(U/L) 30.99(20.92~49.10) 23.45(17.35~31.66) Z=-4.217 <0.001
    ALP(U/L) 70.31±18.64 75.2±23.23 t=-1.597 0.117
    TG(mmol/L) 1.51(1.11~2.24) 1.16(0.90~1.68) Z=-3.508 <0.001
    TC(mmol/L) 5.43±1.01 5.21±1.71 t=0.985 0.326
    HDL(mmol/L) 1.29±0.50 1.33±0.57 t=-0.431 0.667
    LDL(mmol/L) 3.23±0.71 3.28±1.57 t=-0.292 0.771
    FPG(mmol/L) 5.07±1.27 4.66±0.98 t=2.702 0.007
    Bil(μmol/L) 12.98±4.88 14.44±5.39 t=-1.978 0.049
    下载: 导出CSV

    表  3  FTO基因型及等位基因的频率分布

    Table  3.   Frequency distribution of FTO genotypes and alleles

    基因 NAFLD组(n=119) 对照组(n=187) χ2 P OR 95%CI
    rs1421085
      TT 93(78.15) 148(79.57) 0.067 0.795 0.928 0.529~1.628
      CT 23(19.33) 33(17.74)
      CC 3(2.52) 5(2.69)
      T 209(87.82) 329(88.44) 0.055 0.815 0.942 0.570~1.556
      C 29(12.18) 43(11.56)
    rs8050136
      CC 92(77.31) 147(78.61) 0.370 0.831 0.927 0.533~1.612
      CA 23(19.33) 32(17.11)
      AA 4(3.36) 8(4.28)
      C 207(86.97) 326(87.17) 0.005 1.000 0.983 0.606~1.595
      A 31(13.03) 48(12.83)
    rs9939609
      TT 94(79.66) 147(79.46) 1.549 0.213 0.715 0.421~1.214
      AT 23(19.49) 33(17.84)
      AA 1(0.85) 5(2.70)
      T 211(89.41) 327(88.38) 0.153 0.696 1.110 0.658~1.871
      A 25(10.59) 43(11.62)
    注:rs1421085 CC基因型与rs9939609 AA基因型比例低,不适用于χ2检验,因此将其与杂合子合并后进行χ2检验,三个多态性位点基因型的OR值为合并后数据分别与TT、CC、TT基因型比较所得。
    下载: 导出CSV

    表  4  rs1421085、rs9939609、rs8050136不同等位基因携带生化指标比较

    Table  4.   Comparison of biochemical indices of different alleles of rs1421085、rs9939609、rs8050136

    指标 rs1421085 rs9939609 rs8050136
    非C等位基因携带 C等位基因携带 非A等位基因携带 A等位基因携带 非A等位基因携带 A等位基因携带
    BMI(kg/m2) 24.53±3.33 25.03±3.10 24.56±3.33 24.92±3.10 24.54±3.32 25.02±3.13
    ALT(U/L) 20.04(14.7~28.95) 19.59(13.95~29.14) 20.01(14.63~28.65) 20.32(14.10~29.67) 20.01(14.67~28.57) 20.32(13.96~29.89)
    AST(U/L) 20.91(18.48~24.92) 20.37(18.38~25.42) 20.90(18.50~24.82) 20.58(18.24~25.39) 20.87(18.48~24.71) 21.40(18.38~25.44)
    GGT(U/L) 25.52(18.29~35.54) 27.11(18.84~38.38) 25.52(18.22~35.59) 27.11(19.06~36.28) 25.52(18.23~35.63) 27.11(19.01~35.13)
    ALP(U/L) 74.01(58.21~86.44) 66.94(57.62~77.79) 73.86(58.13~86.35) 67.89(58.51~79.50) 74.01(58.21~86.76) 66.94(57.62~77.79)
    FPG(mmol/L) 4.60(4.22~5.13) 4.70(4.20~5.09) 4.60(4.20~5.14) 4.70(4.21~5.09) 4.60(4.22~5.14) 4.66(4.20~5.08)
    TG(mmol/L) 1.26(0.96~1.84) 1.15(0.95~1.67) 1.26(0.97~1.83) 1.15(0.95~1.69) 1.27(0.97~1.84) 1.12(0.94~1.64)
    TC(mmol/L) 5.27(4.65~5.95) 5.11(4.56~5.92) 5.27(4.65~5.95) 5.11(4.58~5.89) 5.27(4.66~5.96) 5.11(4.56~5.85)
    HDL(mmol/L) 1.24(1.07~1.44) 1.24(1.01~1.42) 1.24(1.07~1.44) 1.26(1.06~1.43) 1.24(1.07~1.44) 1.26(1.04~1.42)
    LDL(mmol/L) 3.22(2.72~3.70) 3.13(2.74~3.58) 3.23(2.71~3.71) 3.11(2.75~3.56) 3.23(2.72~3.70) 3.11(2.74~3.55)
    Bil(μmol/L) 13.20(10.20~16.90) 14.45(10.53~17.20) 13.20(10.2~16.85) 14.45(10.33~17.30) 13.20(10.20~16.80) 14.45(10.43~17.30)
    下载: 导出CSV
  • [1] BYRNE CD, TARGHER G. NAFLD: a multisystem disease[J]. J Hepatol, 2015, 62(1 Suppl): S47-S64. DOI: 10.1016/j.jhep.2014.12.012.
    [2] LAN N, LU Y, ZHANG Y, et al. FTO - A common genetic basis for obesity and cancer[J]. Front Genet, 2020, 11: 559138. DOI: 10.3389/fgene.2020.559138.
    [3] KOLAČKOV K, ŁACZMAŃSKI Ł, LWOW F, et al. The frequencies of haplotypes of FTO Gene variants and their association with the distribution of body fat in non-obese poles[J]. Adv Clin Exp Med, 2016, 25(1): 33-42. DOI: 10.17219/acem/60645.
    [4] HUANG S, QIN P, CHEN Q, et al. Association of FTO gene methylation with incident type 2 diabetes mellitus: A nested case-control study[J]. Gene, 2021, 786: 145585. DOI: 10.1016/j.gene.2021.145585.
    [5] BOIKO AS, POZHIDAEV Ⅳ, PADERINA DZ, et al. Search for possible associations of FTO gene polymorphic variants with metabolic syndrome, obesity and body mass index in schizophrenia patients[J]. Pharmgenomics Pers Med, 2021, 14: 1123-1131. DOI: 10.2147/PGPM.S327353.
    [6] LI S, WANG X, ZHANG J, et al. Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease[J]. Braz J Med Biol Res, 2018, 51(8): e7299. DOI: 10.1590/1414-431x20187299.
    [7] CHENG L, YU P, LI F, et al. Human umbilical cord-derived mesenchymal stem cell-exosomal miR-627-5p ameliorates non-alcoholic fatty liver disease by repressing FTO expression[J]. Hum Cell, 2021, 34(6): 1697-1708. DOI: 10.1007/s13577-021-00593-1.
    [8] LIM A, ZHOU J, SINHA RA, et al. Hepatic FTO expression is increased in NASH and its silencing attenuates palmitic acid-induced lipotoxicity[J]. Biochem Biophys Res Commun, 2016, 479(3): 476-481. DOI: 10.1016/j.bbrc.2016.09.086.
    [9] MIZUNO TM. Fat mass and obesity associated (FTO) gene and hepatic glucose and lipid metabolism[J]. Nutrients, 2018, 10(11): 1600. DOI: 10.3390/nu10111600.
    [10] LAU L, WONG SH. Microbiota, obesity and NAFLD[J]. Adv Exp Med Biol, 2018, 1061: 111-125. DOI: 10.1007/978-981-10-8684-7_9.
    [11] STEFAN N, HÄRING HU, CUSI K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies[J]. Lancet Diabetes Endocrinol, 2019, 7(4): 313-324. DOI: 10.1016/S2213-8587(18)30154-2.
    [12] National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association, Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.

    中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
    [13] LIU Q, LIU SS, ZHAO ZZ, et al. TRIB1 rs17321515 gene polymorphism increases the risk of coronary heart disease in general population and non-alcoholic fatty liver disease patients in Chinese Han population[J]. Lipids Health Dis, 2019, 18(1): 165. DOI: 10.1186/s12944-019-1108-2.
    [14] TRÉPO E, VALENTI L. Update on NAFLD genetics: From new variants to the clinic[J]. J Hepatol, 2020, 72(6): 1196-1209. DOI: 10.1016/j.jhep.2020.02.020.
    [15] WIJARNPREECHA K, PANJAWATANAN P, LEKUTHAI N, et al. Hyperuricaemia and risk of nonalcoholic fatty liver disease: A meta-analysis[J]. Liver Int, 2017, 37(6): 906-918. DOI: 10.1111/liv.13329.
    [16] ELOUEJ S, NAGARA M, ATTAOUA R, et al. Association of genetic variants in the FTO gene with metabolic syndrome: A case-control study in the Tunisian population[J]. J Diabetes Complications, 2016, 30(2): 206-211. DOI: 10.1016/j.jdiacomp.2015.11.013.
    [17] INANDIKLIOǦLU N, YAŞAR A. Association between rs1421085 and rs9939609 polymorphisms of fat mass and obesity-associated gene with high-density lipoprotein cholesterol and triglyceride in obese Turkish children and adolescents[J]. J Pediatr Genet, 2021, 10(1): 9-15. DOI: 10.1055/s-0040-1713154.
    [18] WANG L, YU Q, XIONG Y, et al. Variant rs1421085 in the FTO gene contribute childhood obesity in Chinese children aged 3-6 years[J]. Obes Res Clin Pract, 2013, 7(1): e14-e22. DOI: 10.1016/j.orcp.2011.12.007.
    [19] GU Z, BI Y, YUAN F, et al. FTO Polymorphisms are associated with metabolic dysfunction-associated fatty liver disease (MAFLD) susceptibility in the older Chinese Han Population[J]. Clin Interv Aging, 2020, 15: 1333-1341. DOI: 10.2147/CIA.S254740.
    [20] HEBBAR P, ABU-FARHA M, MOHAMMAD A, et al. FTO variant rs1421085 associates with increased body weight, soft lean mass, and total body water through interaction with ghrelin and apolipoproteins in Arab population[J]. Front Genet, 2019, 10: 1411. DOI: 10.3389/fgene.2019.01411.
  • 加载中
表(4)
计量
  • 文章访问数:  1129
  • HTML全文浏览量:  898
  • PDF下载量:  55
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-05-24
  • 录用日期:  2022-06-28
  • 出版日期:  2022-12-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回